AzTrials
AzTrials

Preterm and Term InfantsNCT00747864

Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life

An observational study of Preterm and Term Infants, run by University of Utah.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

S100B, a calcium-binding protein, is found predominantly in the central nervous system (CNS) and is increased in CSF and blood after CNS injury. There are two objectives to this study. Read more about this study

Who is it for?
Ages Up to 48 hoursHealthy volunteers can take part
Conditions the study is for
Preterm and Term Infants
How many people
106 participants
Where
No sites listed yet
Study dates
Apr 2006to Jan 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 48 hours
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: Infants born at >28 weeks gestation will be eligible for enrollment in this study. Infants with fetal malformations, chromosomal anomalies, clinically significant sepsis (retractable hypotension, neutropenia, and thrombocytopenia), or no urine output for the first 48 hours will be excluded. Infants that meet criteria will be enrolled in this study if the parent(s) sign the consent form. There are no patient safety or adverse event issues as this study is non-invasive and observational only.

Who may be able to join

  • Infants born at >28 weeks gestation will be eligible for enrollment in this study.

Who cannot join

  • Infants with fetal malformations, chromosomal anomalies, clinically significant sepsis (retractable hypotension, neutropenia, and thrombocytopenia), or no urine output for the first 48 hours will be excluded.

About this study

S100B, a calcium-binding protein, is found predominantly in the central nervous system (CNS) and is increased in CSF and blood after CNS injury. There are two objectives to this study. 1) To complement our previous study, is urine S100B concentration correlated with gestational age in infants born at > 28 weeks gestation during the first week of life? 2) Is the urine concentration of S100B affected by intracranial pathology in this gestational age range? Elevation of urine concentration of S100B may be an indicator that the infant will develop serious intracranial pathology and may allow for early initiation of treatment to potentially decrease morbidity.

Read the detailed description

S100B is a low molecular weight calcium binding protein found predominantly in the central nervous system (CNS), specifically astroglial cells.[1] S100B plays a role in calcium-dependent information processing and intracellulary is involved in the regulation of cytoskeleton and cell morphology.[1] S100B is secreted by astrocytes and exhibits dose dependent extracellular cytokine functions. In tissue culture at nanomolar concentration, S100B stimulates neuronal growth, development, and regeneration and protects against degeneration. At micromolar concentration, S100B is neurotoxic [2] and stimulates apoptosis potentially through interaction with RAGE receptor, by induction of NO synthase, and through the caspase cascade.

The evidence to support the S100B's role in development and maturation of the CNS is that S100B is differentially distributed in different cortical regions of the brain during fetal development and increases in concentration during gestation.[3] It is postulated that early in development, S100B stimulates glial cell proliferation while later it leads to extension of neurites, regulation of fiber sprouting, formation/maintenance of synapses, and maturation of glial cells.[1] Cord blood concentration of S100B has been shown to be inversely related to gestational age between 27 to 42 weeks gestation.[4] Thirty term infants (37-42 weeks) had mean cord blood S100B concentration of 0.47 ug/L (range 0-1.5ug/L) while 28 preterm infants (27-36 weeks) had a mean cord blood concentration of 1.14ug/L (range 0.5 and 2.7 ug/L). Higher serum concentration of S100B in preterm infants may be due the physiologic increase noted during development and/or lack of integrity of the blood-brain barrier.

S100B is released from damaged astroglial cells and may reflect neuronal damage.[5,6] Concentration of S100B is elevated in cerebrospinal fluid (CSF) of adult patients within 48 hours after infarction and remains elevated for at least 7 days after the event.[6] S100B is also elevated in CSF for the first 3 days after traumatic brain injury [7] and subarachnoid hemorrhage.[8] Due to its low molecular weight, S100B readily crosses a dysfunctional blood-brain barrier and serum concentration of S100B is significantly increased in adult patients after traumatic brain injury [9], stroke [10], or cardiac arrest.[5] Serum S100B rises for 2-4 days after brain trauma or infarct and its concentration correlates with size of damage as identified by CT scan. [9,10] After cardiac arrest, serum S100B concentration was statistically elevated by 30 minutes after initiation of CPR and continued to be significantly elevated in those patients who later exhibited brain damage by CT scan or neurological exam.[5] This significant elevation in serum S100B lasted for at least 7 days. In addition, serum S100B concentration correlated with morbidity [9] and neurological outcome.[10] While the t1/2 of S100B is ~2 hours in adults, persistently increased concentration of S100B in serum indicates continuous release from damaged cells.

The most common CNS trauma for preterm infants is intraventricular hemorrhage (IVH).[11] IVH originates in the microcirculation/capillary network of the germinal matrix. Altered cerebral blood flow secondary to poor cerebral autoregulation or systemic hypo- or hypertension, platelet and coagulation disturbances, infection, and decreased capillary integrity and vascular support have been implicated in the pathogenesis of IVH. IVH is graded (1-4) by extent of hemorrhage seen by ultrasound. In grade I IVH, the blood is confined to the germinal matrix. In Grade II IVH, blood is present in the germinal matrix and a small of blood is present in the ventricles. Grade III IVH occurs when the ventricles are filled with blood and dilated. In Grade IV IVH, blood extends into the brain parenchyma due to venous congestion of the terminal veins that border the lateral ventricles which leads to white matter necrosis. Grades I and II IVH are not associated with an increase in developmental abnormalities, but do not insure normalcy. Grades III and IV IVH (severe IVH) are highly associated with developmental delay, specifically spastic hemiplegia affecting the lower extremities more than the upper extremities due to the proximity of the hemorrhage to the descending motor fibers, and may also affect intellect. IVH, both mild (grade 1-2) and severe (grade 3-4) are rarely seen in infants with gestational age > 28 weeks due to the developmental involution of vessels in the germinal matrix which is the source of this hemorrhage.[11]

Due to its low molecular weight (10.5 kD) and high degree of solubility, S100B is excreted through the kidneys. It has been detected in the first void urine of infants between 26-42 weeks gestation with the most preterm infant exhibiting the highest concentration of S100B (3.17 ug/L).[12] Mean urine S100B concentration in term infants (n=60) was 0.07 ug/L. This study is confounded by no mention of intracranial pathology, insufficient number of preterm infants, and actual data was not shown. In another study, S100B was elevated in urine in preterm infants (29-35 weeks gestation) with IVH (grade 2-4) at birth and continued to increase over the subsequent 3 days when compared to control preterm infants.[13] The severity of IVH significantly correlated with the concentration of S100B in the urine. The highest level of S100B was seen in the five infants who died. An important limitation of the above cited study is insufficient patient enrollment to allow for correlation of both gestational age and presence of severe IVH on urine S100B concentration. Recently, we have shown that urine concentration of S100B is not elevated in very preterm infants (23-28 weeks gestation) without intracranial pathology.[pas abstract] However, very preterm infants with severe IVH (grade 3-4) had significantly elevated urine concentration of S100B on day 1.[14]

The specific aims of this study are to establish baseline S100B concentration in the urine of infants with gestational age > 28 weeks. In addition, the impact of intracranial pathology, that is IVH in preterm infants, will be further investigated. In the previous study, infants who developed necrotizing enterocolitis (NEC) had extremely high levels of S100B in the first week of life. NEC affects preterm infants, mostly 26-32 weeks gestation, and can result in death or markedly increased complications and prolonged length of stay. Secondary analysis of infants in this study will investigate if the development of NEC is significantly associated with a high concentration S100B in the urine. If this is true, one theory to explain this finding is that infants who develop NEC had an event around the time of birth that caused decrease intestinal perfusion allowing increased susceptibility to development of NEC.

Keywords
Gestational Age, Urine, Concentration, of S100B
Medical subject headings
Premature Birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2008 (estimated)
  2. Study startApr 2006
  3. Primary completionDec 2006
  4. Study completionJan 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
106 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00747864
Sponsor's protocol ID
14083
Status last verified
Jul 2010
First submitted
3 Sep 2008
Last updated
23 Jul 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Preterm and Term Infants, run by University of Utah.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jul 2010. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in